We are live on !
Find out more
Lee Ainslie Maverick Capital
AUM
$11.3B
Turnover
71.56%
1-Year Est. Return
76.6%
Lee Ainslie is the founder of Maverick Capital, a long/short equity firm that emerged from the Tiger Management network of investors. Maverick is known for fundamental research, sector specialization among teams, and a classic hedge fund long/short structure. Ainslie’s firm remains a reference name among so-called Tiger Cub managers.
This Fund
S&P 500
This Quarter Est. Return
+47.05%
1 Year Est. Return
+76.6%
3 Year Est. Return
+266.43%
5 Year Est. Return
+219.63%
10 Year Est. Return
+601.38%
AUM
$11.3B
AUM Growth
+$2.65B
(+31%)
Cap. Flow
+$521M
Cap. Flow % of AUM
Cap. Flow %
4.6%
Top 10 Holdings %
Top 10 Hldgs %
42.81%
Holding
327
New
86
Increased
49
Reduced
40
Closed
148
Avg Time Held
Equity + Options
0.6
years
Top 10 Avg Time Held
Equity + Options
0.9
years
Top 20 Avg Time Held
Equity + Options
1.1
years
Avg Time Held Equity only
0.6
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$467M |
| 2 |
Insmed
INSM
|
+$260M |
| 3 |
DPC
DPC Holdings PLC
DPC
|
+$250M |
| 4 |
GFL Environmental
GFL
|
+$240M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$204M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$410M |
| 2 |
Applied Materials
AMAT
|
+$400M |
| 3 |
Argan
AGX
|
+$253M |
| 4 |
TSMC
TSM
|
+$213M |
| 5 |
Linde
LIN
|
+$211M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.07% |
| 2 | Healthcare | 17.67% |
| 3 | Financials | 10.05% |
| 4 | Industrials | 9.89% |
| 5 | Consumer Discretionary | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Vulcan Materials
VMC
$36B
| $188M | 1.66% |
+637,264
| New | +$183M |
2026 Q2
0 quarters
|
|
27
CALL
Nu Holdings
NU
$58.2B
| $188M | 1.66% |
+14,047,600
| New | +$189M |
2026 Q2
0 quarters
|
|
28
Carvana
CVNA
$75.4B
| $174M | 1.53% |
2,638,673
+537,293
| +26% | +$38M |
2025 Q3
3 quarters
|
|
29
Southwest Gas
SWX
$6.75B
| $168M | 1.48% |
1,889,558
-237,369
| -11% | -$21.2M |
2023 Q4
10 quarters
|
|
30
Coca-Cola
KO
$399B
| $163M | 1.44% |
2,006,974
+722,362
| +56% | +$57M |
2025 Q3
3 quarters
|
|
31
Performance Food Group
PFGC
$15.3B
| $141M | 1.25% |
+1,261,179
| New | +$120M |
2026 Q2
0 quarters
|
|
32
Voya Financial
VOYA
$8.91B
| $120M | 1.06% |
+1,324,081
| New | +$108M |
2026 Q2
0 quarters
|
|
33
NewAmsterdam Pharma
NAMS
$2.48B
| $111M | 0.98% |
3,267,802
+1,081,400
| +49% | +$35.6M |
2024 Q4
6 quarters
|
|
34
Bio-Techne
TECH
$11.4B
| $108M | 0.96% |
1,535,610
-3,204,111
| -68% | -$173M |
2025 Q3
3 quarters
|
|
35
Roivant Sciences
ROIV
$27.1B
| $100M | 0.88% |
2,829,024
+1,202,084
| +74% | +$35.5M |
2026 Q1
1 quarter
|
|
36
Fluor
FLR
$6.36B
| $97.3M | 0.86% |
1,857,157
+441,600
| +31% | +$21.6M |
2026 Q1
1 quarter
|
|
37
Veradermics Inc
MANE
$6.01B
| $97.1M | 0.86% |
+789,980
| New | +$74M |
2026 Q2
0 quarters
|
|
38
Mirion Technologies
MIR
$4.58B
| $94M | 0.83% |
5,245,039
+2,595,160
| +98% | +$48.1M |
2026 Q1
1 quarter
|
|
39
Vaxcyte
PCVX
$9.9B
| $93.8M | 0.83% |
1,613,242
+235,504
| +17% | +$12.8M |
2024 Q1
9 quarters
|
|
40
Novo Nordisk
NVO
$173B
| $79.3M | 0.7% |
1,653,872
-426,249
| -20% | -$18.3M |
2026 Q1
1 quarter
|
|
41
Compass
COMP
$7.21B
| $72.9M | 0.64% |
5,912,783
+740,387
| +14% | +$6.17M |
2025 Q4
2 quarters
|
|
42
Merit Medical Systems
MMSI
$5.58B
| $67.9M | 0.6% |
978,617
+264,536
| +37% | +$17.5M |
2025 Q1
5 quarters
|
|
43
Belite Bio
BLTE
$6.05B
| $61M | 0.54% |
+396,311
| New | +$60.7M |
2026 Q2
0 quarters
|
|
44
Wave Life Sciences
WVE
$716M
| $59.7M | 0.53% |
10,278,115
+116,716
| +1% | +$774K |
2021 Q1
21 quarters
|
|
|
45
CALL
Fluor
FLR
$6.36B
| $52.7M | 0.47% |
+1,006,500
| New | +$49.3M |
2026 Q2
0 quarters
|
|
46
uniQure
QURE
$1.75B
| $42.6M | 0.38% |
925,383
+227,743
| +33% | +$5.96M |
2025 Q4
2 quarters
|
|
47
Invivyd
IVVD
$177M
| $16.6M | 0.15% |
18,970,913
| – | – |
2023 Q1
13 quarters
|
|
48
Rocket Pharmaceuticals
RCKT
$279M
| $13.4M | 0.12% |
3,923,963
+356,591
| +10% | +$1.19M |
2021 Q2
20 quarters
|
|
49
Abivax
ABVX
$7.8B
| $5.33M | 0.05% |
+40,000
| New | +$4.53M |
2026 Q2
0 quarters
|
|
50
Celestica
CLS
$35.7B
| $4.67M | 0.04% |
12,782
+1,209
| +10% | +$454K |
2026 Q1
1 quarter
|
|
Similar funds
GJL
Lee Ainslie's Q2 2026 Portfolio in Review
As of Q2 2026, Lee Ainslie held 327 positions worth $11.3B, up 31% from $8.67B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Lee Ainslie deployed $521M of net new capital in Q2 2026, opening 86 new positions and adding to 49 existing holdings. Its largest new stake was Meta Platforms (Facebook): 764,041 shares worth $430M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 29% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was ASML, an estimated $410M trimmed.
- Lee Ainslie's largest Q2 2026 buy was Meta Platforms (Facebook): 764,041 shares worth $430M.
- Lee Ainslie added most to GFL Environmental in Q2 2026, an estimated $240M increase.
- Lee Ainslie's biggest Q2 2026 reduction was ASML, cutting an estimated $410M.
- Lee Ainslie fully exited Argan in Q2 2026, selling an estimated $253M.
- Lee Ainslie's ten largest holdings make up 43% of its $11.3B portfolio in Q2 2026.
- Lee Ainslie opened 86 new positions and closed 148 in Q2 2026.
- Lee Ainslie's portfolio value rose 31% quarter-over-quarter to $11.3B.
Based on Maverick Capital's 13F filing for Q2 2026, filed 14 Aug 2026.